According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
Other research analysts have also issued reports about the stock. BidaskClub upgraded shares of Karyopharm Therapeutics from a buy rating to a strong-buy rating in a research note on Friday, December 20th. Bank of America raised shares of Karyopharm Therapeutics from an underperform rating to a neutral rating in a report on Friday, January 3rd. Robert W. Baird set a $25.00 target price on Karyopharm Therapeutics and gave the stock a buy rating in a research report on Tuesday, September 24th. Wedbush raised their price target on Karyopharm Therapeutics from $15.00 to $18.00 in a report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. raised their price target on Karyopharm Therapeutics from $23.00 to $27.00 and gave the stock an overweight rating in a report on Thursday, January 9th. Four equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Karyopharm Therapeutics presently has a consensus rating of Buy and an average price target of $22.14.
NASDAQ KPTI opened at $17.04 on Thursday. The company has a market cap of $1.07 billion, a PE ratio of -4.97 and a beta of 2.59. Karyopharm Therapeutics has a 52 week low of $3.92 and a 52 week high of $20.09. The company has a quick ratio of 7.16, a current ratio of 7.16 and a debt-to-equity ratio of 2.03. The firm’s 50-day simple moving average is $17.97 and its two-hundred day simple moving average is $12.33.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Monday, November 4th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.17. The firm had revenue of $13.15 million during the quarter, compared to the consensus estimate of $1.61 million. Karyopharm Therapeutics had a negative net margin of 909.24% and a negative return on equity of 187.25%. As a group, equities research analysts anticipate that Karyopharm Therapeutics will post -3.12 EPS for the current year.
In related news, Director Mansoor Raza Mirza sold 2,944 shares of Karyopharm Therapeutics stock in a transaction on Friday, December 27th. The stock was sold at an average price of $20.00, for a total value of $58,880.00. Following the completion of the sale, the director now owns 2,944 shares of the company’s stock, valued at $58,880. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael Kauffman sold 20,000 shares of the company’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $14.17, for a total value of $283,400.00. Insiders have sold a total of 135,463 shares of company stock worth $2,182,510 in the last 90 days. Company insiders own 11.63% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Orbimed Advisors LLC bought a new stake in shares of Karyopharm Therapeutics in the second quarter worth about $18,859,000. Point72 Asset Management L.P. purchased a new position in Karyopharm Therapeutics during the 2nd quarter valued at approximately $15,552,000. State Street Corp increased its stake in Karyopharm Therapeutics by 181.2% in the 3rd quarter. State Street Corp now owns 3,148,516 shares of the company’s stock worth $30,289,000 after acquiring an additional 2,028,790 shares during the last quarter. Nuveen Asset Management LLC bought a new stake in Karyopharm Therapeutics in the 2nd quarter worth approximately $2,310,000. Finally, Vanguard Group Inc. raised its holdings in shares of Karyopharm Therapeutics by 14.1% during the 2nd quarter. Vanguard Group Inc. now owns 2,983,862 shares of the company’s stock worth $17,874,000 after acquiring an additional 369,590 shares in the last quarter. 93.12% of the stock is owned by institutional investors.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).
Further Reading: Using other technical indicators with support levels
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.